
A chlamydia vaccine has shown to be safe in a Phase 1 clinical trial, according to a study published in …

Health professionals in the Democratic Republic of Congo (DRC) are now offering two experimental drugs to people infected with Ebola, …

The Scottish Medicines Consortium (SMC) has turned down Vertex’ cystic fibrosis drug Orkambi on the grounds that it is not …

Cambridge, Massachusetts-based Brammer Bio is planning to set up a new manufacturing facility in Norton, Massachusetts. The Thermo Fisher subsidiary …

The FDA-approved anti-parasitic drug nitazoxanide could be used as a treatment for Ebola, according to researchers from the Boston Children’s …

European health experts have warned that a no-deal Brexit could worsen medicines shortages in the European Union. Speaking to Reuters, …

Five senators, including presidential candidates Bernie Sanders and Elizabeth Warren, have condemned Novartis for using “falsified data… to obtain approval …

A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel. …

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …

The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …

Researchers from the University of Pittsburgh, working with the biotech Lentigen, have found that an advanced form of CAR-T therapy …

AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …

Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics in a deal worth $600 …

Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …

Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …

MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …

Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …

Rhythm Pharma’s obesity drug setmelanotide achieved positive results in two pivotal Phase 3 trials. In both studies, setmelanotide met its …

As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …